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Abstract
The S100 proteins contain two EF-hand motifs and are of generally unknown function. One of these proteins, S100A4, is
an intracellular calcium-binding protein that is present in normal rodent and human cells. In cultured rodent mammary cells,
S100A4 is expressed at a higher level in some metastatic epithelial cells than in non-metastatic counterparts. Similarly, in
human breast cell lines, S100A4 is present at a higher level in cultured cells from the more malignant, than in those from the
more benign tumours. Gene transfer experiments have shown that rodent or human S100A4 is able to induce metastatic
capability in otherwise non-metastatic breast tumour cells. Furthermore, expression of rodent S100A4 transgenes can induce
metastasis of benign tumours arising in transgenic model systems. Possible mechanisms for the metastasis-inducing effect of
S100A4 and the relevance of these observations to human cancer are discussed. ß 1998 Elsevier Science B.V. All rights
reserved.
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1. Nomenclature and early descriptions of S100A4
S1004 is known by a variety of names which refer
to the protein, p9Ka [1,2], calvasculin [3], CAPL [4],
or a cDNA, mts1 [5], pEL98 [6], 18A2 [7], 42A [8],
fsp (¢broblast speci¢c protein) [9] mainly from ro-
dent and human cells. Many of the original cloned
DNAs arose from di¡erential screening experiments
in which cDNAs to mRNA populations were com-
pared in cultured cells before and following a variety
of treatments. For example, S100A4 mRNA was re-
ported to be up-regulated when quiescent BALB/c
3T3 mouse ¢broblasts were stimulated to grow with
serum [7], or when mRNA from cultured mouse ¢-
broblasts was compared with mRNA from primary
cultures of mouse embryo ¢broblasts [6]. S100A4
mRNA was up-regulated in carcinogen- or onco-
gene-transformed ¢broblasts [6]. More recently,
S100A4 mRNA and protein have been shown to be
increased in NIH 3T3 ¢broblasts or in normal rat
kidney cells transformed by v-Ki-ras, v-Ha-ras or
v-src [10,11]. S100A4 mRNA is up-regulated when
epithelial cells are induced to change morphology,
for example when normal rat mammary cells [12]
or benign mammary tumour cells [1] spontaneously
convert to an elongated morphology in culture. Sim-
ilarly, S100A4 has been identi¢ed as an up-regulated
¢broblastic mRNA in a di¡erential screen between
murine tubulointestinal ¢broblasts and isogenic
proximal tubule cells of the kidney [9]. The up-regu-
lation in these situations may be related to the epi-
thelial/mesenchymal conversion described in ¢bros-
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ing kidney, and S100A4 has been proposed to be an
early event in such a conversion [13]. S100A4 mRNA
is induced (together with S100A10 mRNA) [8], when
rat pheochromocytoma cells are induced to elongate
with nerve growth factor. Thus, elevated levels of
S100A4 have been described in association with
growth and morphological changes in cultured cells
from a variety of origins. In rat sciatic nerve, S100A4
mRNA level increases in the distal portion following
a crush injury [14], showing that S100A4 mRNA can
also be modulated in vivo.
2. Distribution of S100A4 protein in normal tissues
S100A4 is widely distributed in normal tissues,
usually showing a highly speci¢c cell type distribu-
tion, and it has been necessary to use immunocyto-
chemical techniques with highly speci¢c antisera to
obtain the precise distribution of S100A4. Cells
which stain strongly for S100A4 in the rat include
the proximal and distal tubules of the kidney, the
ducts of the parotid salivary gland, which are in-
volved in changing the composition of the saliva,
the parietal cells of the stomach and the absorptive
cells, but not the mucous-secreting cells, of the intes-
tine [15,16]. A common feature of all these cells
would seem to be their involvement in processes of
ion transport. However, a more restricted pattern of
expression has been reported in the kidney by others
[9]. S100A4 seems to be generally produced at only a
very low level in brain, but some peripheral neuronal
cells stain weakly, and S100A4 mRNA increases in
rat sciatic nerve 14-fold between days 2 and 23 post-
natally [14]. S100A4 is associated with the smooth
muscle of the gut, and the smooth muscle of arteries
and other blood vessels [15]. In capillaries, however,
which do not possess a smooth muscle wall, S100A4
is found in the endothelial cells [15,16]. In the im-
mune system there is staining of particular cells in
the spleen, marrow and lymph glands, and in the
blood, occasional white cells are stained [15]. In hu-
mans, S100A4 has been found in bone marrow,
spleen, lymphocytes and at a particularly high level
in peritoneal macrophages [17]. S100A4 mRNA is
not expressed in the mouse embryo until day 12.5,
when it becomes detectable in ¢broblastic cells in a
variety of locations [9].
3. S100A4 protein
S100A4 is a polypeptide of 100 amino acids, ex-
cluding the initiating N-terminal methionine (Fig. 1).
The molecular mass of the natural protein, deter-
mined by electrospray ionisation mass spectrometry,
11 646 Da, di¡ers from that of the recombinant pro-
tein (11 594 Da), re£ecting the former’s N-terminal
acetylation; however, natural S100A4 is otherwise
unmodi¢ed [18]. S100A4 has two EF-hand structures
Fig. 1. The primary structures of rat and human S100A4 and a comparison with rat and human S100A6 (calcyclin). The amino acid
sequences of rat and human S100A4 and S100A6 are shown as one-letter amino acid code and are aligned with one another. The he-
lix^loop^helix regions of the two EF hands are shown as solid lines above the sequence with the calcium ligands of the calcium-bind-
ing loop marked with asterisks. Amino acid residues important for the dimer interface of S100A6 [22] are shown in bold and under-
lined above the vertical arrows. Amino acids in the equivalent positions of S100A4 are similarly indicated.
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(Fig. 1), which conform to the variant forms of S100
proteins, separated by a short spacer. The C-terminal
tail region is longer than for some other S100 pro-
teins (Fig. 1). S100A4 has been puri¢ed from natural
sources [19] and also produced in recombinant form
[20]. Upon reverse phase HPLC, natural S100A4 be-
haves as a highly hydrophobic protein, being eluted
by a high acetonitrile concentration [19]. However,
puri¢cation is more conveniently carried out by a
two-step procedure of ion exchange chromatography
followed by chromatography on phenyl^Sepharose.
S100A4 is eluted from the phenyl^Sepharose by re-
moving calcium ions with EGTA [20]. There is evi-
dence that S100A4 forms non-disul¢de dimers, at
least in vitro [3,18]. Although these observations
need to be interpreted with caution, the conservation
in S100A4 of four out of ¢ve amino acids thought to
be important contacts in the dimer interface in di-
meric S100A6 (calcyclin) [21,22] strongly suggests
that S100A4 can also exist in a homodimeric form
through hydrophobic, and not disul¢de, interactions
(Fig. 1).
Natural rat and recombinant rat S100A4 proteins
bind calcium ions with similar a⁄nities [19,20]. In
one series of experiments, the Kd was found to be
38 WM with respect to calcium in minimal levels of
other monovalent or divalent cations [20]. However,
unexpectedly for an intracellular calcium-binding
protein, potassium and magnesium ions were
strongly antagonistic of calcium binding in vitro,
raising the Kd more than sixfold and threefold, re-
spectively, at near physiological concentrations of
ions (Table 1). A lower a⁄nity of S100A4 for calci-
um and no e¡ect of magnesium ions, has been re-
ported [18], a result that is entirely consistent with
the high level of potassium ions used in their bu¡ers.
These e¡ects of divalent and monovalent cations
could be associated with the regulation of S100A4
activity in those cells which are involved in ion trans-
port, in which case, the modulation of calcium bind-
ing by potassium might have physiological signi¢-
cance.
4. Gene structure and regulation
The transcribed S100A4 gene consists of two cod-
ing exons, each of which contains DNA correspond-
ing to the region around one of the EF-hand motifs,
and one small non-coding 5P exon. The intron which
separates this small 5P exon appears to be of regula-
tory signi¢cance, since in rats and mouse there is a
region with homology to the T cell, CD3N, enhancer
[23,24]. In the mouse, footprinting analysis in vitro
showed that a 16 bp region was protected using ex-
tracts from either high- or low-expressing S100A4
cell lines; however, footprinting in vivo showed pro-
tection only in the high-expressing cells and not in
the low-expressing cells [23]. In the rat, a similar
protection in high- and low-expressing cell lines is
evident in vitro, and the same region is only pro-
tected in vivo in high-expressing cell lines. However,
the precise region that is protected is not exactly the
same in the two species [24]. More recently, Lukani-
din’s group, in an elegant series of experiments, have
identi¢ed a sequence resembling an NFUB-related
Table 1
Calcium-binding parameters of S100A4 and calmodulin determined by £ow dialysisa
Protein Concentration of protein (WM) Additionsb Kd (WM)
Calmodulin 4.4 None 7.4
S100A4
pH 8.0 38.5 None 37.0 þ 0.5
pH 7.2 38.5 None 34 þ 0.5
pH 7.2 7.7 None 38 þ 0.6
pH 7.2 38.5 5 mM Mg2 97 þ 0.2
pH 7.2 38.5 100 mM K 161 þ 0.2
pH 7.2 38.5 100 mM Na 139 þ 0.6
aRef. [20].
bBu¡er = MOPS/Tris at pH and with additions indicated.
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binding site which forms a complex with a 200 kDa
protein [25]. In the mouse, this sequence is active in
vitro in both high and low-expressing cells; however,
in vivo the complex only forms in the high-expressing
cells [25]. Although the NFUB-like site is di¡erent
between mouse and human, the complex with the
200 kDa protein is also detected with the homolo-
gous human sequence [25].
In cultured mouse [26] and rat [24] cells, and also
in cultured human lymphoma cells [27], the S100A4
gene is methylated in low-expressing cells, but less
methylated in high-expressing cells. A di¡erence be-
tween the mouse and the rat S100A4 genes in this
regard is a potentially regulatory AP1 site in the ¢rst
intron formed by methylation in the mouse [28];
however, this sequence is not present in the rat [29]
and only partially conserved in the human S100A4
gene intron sequences.
A further di¡erence in the regulation of transcrip-
tion between the rat and the mouse S100A4 genes
concerns the upstream regulatory regions. In the
mouse, no active cis-acting upstream regulatory ele-
ments were identi¢ed in mammary tumour-derived
cell lines [26]. However, an unidenti¢ed region within
the upstream 1800 bp of the mouse S100A4 gene has
been reported to be active in mouse ¢broblasts, but
inactive in epithelial cells [9]. In the rat, a sequence,
1300 bp upstream of the start site of transcription, is
related to the recognition sequence for GC-factor, an
inhibitory transcription factor [30]. This sequence
binds a factor which also recognises the GC-factor
consensus sequence [29]. Binding of the inhibitory
factor in low-expressing epithelial cells has been de-
tected by DNAse footprinting in vitro and DNA
footprinting in vivo (Fig. 2), and by gel mobility shift
assays [29]. In a range of epithelial and epithelial-
derived rat cells, which express S100A4 mRNA,
there is a reduced level of a mRNA which hybridises
Fig. 2. A summary of footprinting experiments de¢ning an up-
stream regulatory region of the rat S100A4 gene. The location
of the GC-factor like recognition sequence is shown diagram-
matically relative to the TATA box, ¢rst and second exons of
the S100A4 gene. The sequence surrounding the GC-factor-like
recognition sequence is shown in double-stranded form. Lines
below each strand of sequence show the extent of the in vitro
footprint, and the asterisks show protected G nucleotides aris-
ing from in vivo footprinting.
Fig. 3. Identi¢cation of S100A4 in Rama 800, a metastatic rat
mammary epithelial cell line, but not in the benign rat mam-
mary cell line, Rama 37. Cells were labelled with
[35S]methionine during culture and harvested into a denaturing
bu¡er, and the extracts subjected to two-dimensional polyacryl-
amide gel electrophoresis using denaturing isoelectric focusing
in the ¢rst dimension and SDS^polyacrylamide gel electropho-
resis in the second dimension. Following staining, destaining
and drying, the gels were subjected to autoradiography. The ar-
row on the right-hand panel points to the radioactive spot cor-
responding to S100A4 in the metastatic Rama 800 cells, and
the arrow on the left-hand panel points to the corresponding
position, where there is only very faint spot corresponding to
S100A4 in the non-metastatic Rama 37 cells. IEF, isoelectric fo-
cusing; kd, molecular mass in kDa; SDS, sodium dodecyl sul-
fate^polyacrylamide gel electrophoresis. Reprinted from The
Stem Cells Handbook by C.S. Potter (1997) with permission of
the publisher, Academic Press.
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to a GC-factor cloned cDNA compared with non-
S100A4 expressing cells [29]. In these cells there is a
correlation not only between the degree of protection
in footprinting experiments and the level of this
mRNA, but also an inverse correlation between the
level of this GC-factor-hybridising mRNA and the
level of S100A4 mRNA, suggesting that a reduced
level of the GC factor-like activity might be respon-
sible, in part, for the up-regulation of S100A4
mRNA in the high S100A4 expressing cells [29].
In the rat cells, transcription of the S100A4 gene
seems to be regulated by positive regulatory factors
associated with the TATA box [29], with the ¢rst
intron [24], a negative upstream regulatory element
[29] and DNA methylation [31]. The rat S100A4 gene
does not contain an associated CpG island. Using
bisul¢te mapping techniques, methylcytosine is essen-
tially absent from the upstream regulatory region in
high and low expressing cell lines, whereas methylcy-
tosine is detectable in the TATA box and ¢rst intron
positive regulatory regions in low-expressing cell
lines, but less so in high-expressing cell lines [31].
5. Association of S100A4 with processes leading to
metastasis of cancer cells
The mRNAs for rat and mouse S100A4s are
present at an abundant level in epithelial cell lines
which possess metastatic properties in in vivo animal
model systems, whereas related cell lines which are
not metastatic in these systems contain only low or
undetectable levels of S100A4 mRNA [5,32]. In the
rat systems this extends to the protein, as detected
by its characteristic migration position following
two-dimensional gel electrophoresis (Fig. 3). A ma-
jor step forward came with the demonstration that
experimental elevation of S100A4 by transfection of
a benign non-metastatic rat mammary cell line,
Rama 37, with multiple copies of the rat S100A4
gene in an expression vector induced, in some of
the cells, the capability to metastasise from the mam-
mary gland to the lungs and lymph nodes in synge-
neic experimental rats, showing that S100A4 was
able to cause metastasis in a suitable experimental
system [33]. Similar experiments have shown that the
human S100A4 has the same capability in the rat
model system (Table 2) [34], and mouse S100A4 is
able to induce malignant/invasive and metastatic
properties tested in the immunode¢cient nude mouse
in the human breast carcinoma-derived cell line,
MCF-7 [35]. This cell line is normally not metastatic
in the immunode¢cient nude mouse. These results
taken together indicate that the induction of a de-
tectable metastatic phenotype in cultured cells is a
general property of rat, mouse and human S100A4
proteins, and that S100A4 can exert its e¡ect on
rodent or human cells. However, transfection of cul-
Table 2
Induction of metastasis in benign tumour-derived rat mammary epithelial cells by human S100A4
Cellsa Level of rat S100A4
mRNA (arbitrary units)b
Level of human S100A4
mRNA (arbitrary units)b
Incidence of
tumoursc
Incidence of
metastasesd
Untransfected/neo transfected recipient be-
nign tumour cells
+e 3e 22/26f 0/20f
Recipient cells transfected with pSV2neo and human S100A4 gene
Pool 1 + 3 24/30g 0/30
Pool 2 + +++ 31/40g 20/30h
aBenign rat mammary tumour cells were co-transfected with pSV2neo and with DNA consisting of the entire human S100A4 gene [34].
bThe level of rat and human S100A4 mRNAs in the cells was determined by reverse transcription PCR speci¢c for the rat and human
S100A4 mRNAs. Levels represent intensities of bands following agarose gel electrophoresis of the PCR products.
cNumber of tumours/number of sites inoculated.
dNumber of animals with metastases/number of animals with tumours.
eDetermined on pSV2neo-transfected benign rat mammary tumour cells.
f Determined on untransfected benign rat mammary tumour cells.
gTumour incidence not signi¢cantly di¡erent from benign rat mammary tumour cells (Ps 0.4; Fisher’s exact test).
hSigni¢cantly more metastases than benign rat mammary tumour cells (P6 0.0001; Fisher’s exact test).
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tured cells with an expressed gene and the transfer of
the cells into the mammary glands of host animals is
not a complete model of cancer, since spread of the
cells in this model might be a consequence of the
injection procedure.
In order to investigate the metastasis-inducing
properties of S100A4 in cells in a normal tissue en-
vironment, transgenic mice have been produced
which contain multiple additional copies of the
S100A4 gene regulated by the natural rat promoter
of the S100A4 gene [36]. The mice contain elevated
levels of immunocytochemically determined rat
S100A4 in their tissues. These mice develop nor-
mally, display no detectable phenotype and have a
normal life span. They do not show a higher inci-
dence of tumour formation than non-transgenic mice
of the same strain. The distribution of the rat
S100A4 mRNA in the tissues of the transgenic
mice was precisely that found in the normal rat
even though it was being expressed in mouse cells
[36]. This is not unexpected, since the rat S100A4
transgene was expressed from its own promoter in
these transgenic mice. The result shows that the
S100A4 transgene contains all the signals required
to direct its own expression to normal tissues, and
that these rat signals are functional in the mouse
cells. These transgenic mouse strains provide a
unique opportunity to examine the comparative tis-
sue distribution of the rat and mouse mRNAs for
S100A4 in the same animal environment. Using spe-
ci¢c probes in Northern blotting experiments, it was
possible to show clearly that there is a di¡erent dis-
tribution between rat and mouse S100A4 mRNAs.
The mouse mRNA is present at very high level in
tissues of the immune system, spleen, thymus and
lymph node, whereas the rat S100A4 mRNA is
present at its highest level in lung. The distribution
of S100A4 in rat and mouse cells is surprisingly dif-
ferent in two species as closely related as rat and
mouse [36].
Since S100A4 is not able to induce tumour forma-
tion on its own, the S100A4 transgenic mice were
mated with mice bearing the oncogene, neu, which
is the activated rodent homologue of the human c-
erbB-2 oncogene. Human c-erbB-2 is evident on the
surface membranes of cells in 20^30% of human
breast cancers and is prognostic of a poor outcome
of the disease [37]. In the transgenic mice, the neu
oncogene is under the control of the mouse mam-
mary tumour virus long terminal repeat and expres-
sion of the neu transgene becomes activated after the
mice have undergone multiple pregnancies, resulting
in stochastic mammary neoplasia between 7 and 14
months of age [38]. In transgenic mice bearing neu-
induced tumours, Neu protein is expressed at a high
level on the membranes of tumour cells, but not on
the normal mammary cells. When the neu transgenic
Fig. 4. One e¡ect of S100A4 on metastasis of neu-induced
mammary tumours in transgenic mice. Stained histological sec-
tions are from the lungs of a female transgenic mouse which
had inherited the neu transgene (a) and from a female transgen-
ic mouse which had inherited both the neu and S100A4 trans-
genes (b). Both animals had primary tumours in the mammary
glands. Panel (b) reprinted from Ref. [39] with permission of
the publisher, Stockton Press.
BBAMCR 14411 3-12-98
R. Barraclough / Biochimica et Biophysica Acta 1448 (1998) 190^199 195
mice were mated with the S100A4 transgenic mice,
o¡spring which inherited the S100A4 transgene
yielded no tumours as expected [39]. O¡spring which
inherited the neu oncogene succumbed to stochastic
mammary neoplasias after multiple pregnancies, with
50% of the mice yielding tumours at about 14.5
months; however, there were no observable growing
metastases in the lungs (Fig. 4) or in other tissues
examined [39]. Mice which inherited both the
S100A4 and neu transgenes yielded stochastic mam-
mary tumours after multiple pregnancies, with 50%
of the mice yielding tumours at 11.4 months. In 10
out of 17 mice examined, metastases were present in
the lungs, constituting up to 24% of the area of his-
tological sections of the lungs (Fig. 4), and the tu-
mour tissue was invasive [39].
Similar results have been obtained by combining
an independent mouse model system containing mur-
ine S100A4 transgenes, and mating these mice with
the GS/A mouse strain which has a high incidence of
spontaneous mammary tumours [40]. These results
taken together clearly show that S100A4 is not itself
able to induce tumorigenesis, and its metastasis-in-
ducing capability becomes evident in cells which have
otherwise acquired tumorigenic potential.
The causative relationship between S100A4 and
metastasis has been further established in human
metastatic osteosarcoma cells, which express high
levels of S100A4. These cells have been transfected
with a hammerhead ribozyme directed against
S100A4 transcripts. The e¡ect of the ribozyme was
to reduce the capacity of the cells to give skeletal
metastases following cardiac injection into nude
mice [41]. In a similar series of experiments, Lewis
lung carcinoma cells were engineered to contain an
inducible expression plasmid encoding antisense
S100A4 mRNA. Activation of the antisense con-
struct reduced the motile and invasive behaviour of
the cells, and reduced their ability to colonise the
lungs when the cells were injected into the tail vein
of the recipient mice [42]. These experiments show
that it is possible to reverse the e¡ects of S100A4.
Colonisation of the lungs/skeletal muscle represents
only one part of the metastatic cascade, thus, on face
value, these experiments suggest that S100A4 a¡ects
the later stages of metastasis, survival in the circula-
tion and/or the establishment of colonies at the sec-
ondary site.
6. Mode of action of S100A4
Several lines of evidence suggest an involvement of
S100A4 in processes of cell motility. S100A4 has
been immuno£uorescently localised to the cytoskele-
ton when cultured cells are stained with antibodies to
S100A4 [17,20,33], and this staining seems to be
identical to the pattern of staining obtained using
phalloidin, which interacts with actin-containing ¢l-
aments in the cell [17,20,33]. In HL-60 promyelocytic
leukaemia cells treated with phorbol 12-myristate 13
acetate (PMA), dimethylsulfoxide (DMSO) or all-
trans retinoic acid, the induction of S100A4 by
PMA and DMSO coincides with the acquisition of
cell motility [43]. In a group of untransformed and
corresponding transformed mouse cells, the level of
S100A4, or its mRNA, correlates with the motility of
the cells on a ¢bronectin/colloidal gold substratum
[43]. In a variant v-src transformed cell line of low
S100A4 level, and low cell motility, raising the level
of S100A4 by transfecting the cells with additional
copies of a mouse S100A4 cDNA, not only raised
the S100A4 level, but also increased the cells’ motil-
ity [43]. Non-metastatic mouse mammary adenocar-
cinoma cells transfected with the S100A4 gene and
expressing S100A4 protein showed altered morphol-
ogy, and increased motility in a Boyden Chamber
assay [44]. However, the cells did not show increased
invasion through Matrigel in vitro, nor increased
metastasis in vivo in these experiments [44].
By analogy with other calcium-binding proteins,
binding partners have been sought for S100A4. In
common with other members of the S100A family,
many binding partners have been identi¢ed, and it is
not yet clear which particular interactions of S100A4
mediate its metastasis-inducing properties. Some cor-
relations have been reported which have been inter-
preted as involvement of S100A4 in the depolymer-
isation of tubulin [45] and in the sequestration of p53
by S100A4 [46,47]; however, there is as yet little
evidence of direct interactions to support these hy-
potheses. Direct calcium-dependent interactions in
vitro have been reported between S100A4 and sev-
eral separate cytoskeletal components, F-actin [48],
amino acid residues 39^107 of non-muscle tropo-
myosin [49], and non-muscle myosin molecules [50^
53] under a variety of interacting conditions. In the
case of non-muscle myosin, deletion mapping experi-
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ments have identi¢ed the S100A4 binding region
close to the C-terminus of the myosin heavy chain
[53]. S100A4 might act by destabilising myosin ¢la-
ments [52], and it has been shown that S100A4 in-
hibits the actin-activated myosin ATPase of non-
muscle myosin in a calcium dependent manner, but
not the same activity of non-muscle myosin heavy
meromyosin, suggesting that it is the binding of
S100A4 to the C-terminal region of the myosin heavy
chains that in£uences ATPase activity [52].
S100A4 binds to a region of the myosin heavy
chain which can be phosphorylated in vitro by pro-
tein kinase C [53]. This is a potentially interesting
observation because there have been reports, over a
number of years, of interactions of other S100 pro-
teins being associated with the modulation of protein
kinase activity and more speci¢cally of protein kinase
C (PKC) activity. Thus, S100A10 interacts with the
cytoskeletal p36, a substrate for viral tyrosine kinases
[54], an interaction which it has been suggested in-
hibits the phosphorylation of p36. S100A1, in dimer-
ic form, interacts with the giant myosin-associated
twitchin kinases of aplysia [55] and Caenorhabditis
elegans [56], and stimulates in a calcium-dependent
manner their kinase activity up to over 1000-fold
[57], by relieving the twitchin kinase auto-inhibitory
activity [55]. The related S100b (LL) protein has been
reported to interact with the microtubule associated
protein, d and to inhibit its phosphorylation by calm-
odulin-dependent protein kinase II [58]. S100b/L has
been reported to inhibit protein kinase C-mediated
phosphorylation of the nervous-system growth-asso-
ciated protein (GAP)-43 [59,60], PKC-dependent
phosphorylation of p53 [61] and of derivative pepti-
des [62]. Thus it is possible that, as suggested before
[58], the S100 proteins, including S100A4, might be
involved in the modulation of speci¢c phosphoryla-
tion events in the cell.
7. S100A4 in human tumours
Since rodent and human S100A4 proteins are able
to induce metastasis in a variety of model systems, it
is possible that S100A4 protein might be associated
with breast cancer in humans. S100A4 mRNA is
present at a high level in malignant breast cancer-
derived cell lines, such as MDA-MB-231 and SK-
Br-3, than cell lines derived from benign breast tu-
mours, or SV40 virus-transformed normal human
breast epithelial cells (Lloyd and Barraclough, un-
published data).
S100A4 mRNA is present at a higher level in ma-
lignant breast cancer specimens than in benign breast
lesions, and in the malignant specimens there was a
statistically signi¢cant inverse correlation between
the level of S100A4 mRNA detected by Northern
blotting and immunocytochemically detected oestro-
gen receptor level (Lloyd and Barraclough, unpub-
lished data). A similar approach has suggested that a
high level of mRNA for S100A4 in in¢ltrating ductal
carcinoma of the breast is associated with spread to
the local lymph nodes [63]. Using a Western blotting
approach on breast tumour specimens, the level of
S100A4 protein was found to correlate with the level
of activity of urokinase-like plasminogen activator,
but not with another marker of malignancy, cathep-
sin D [64]. S100A4 mRNA has also been detected
using Northern blotting, in melanocytic lesions, but
its presence failed to correlate with indicators of tu-
mour progression [65]. However, since all these re-
sults rely on Northern or Western blotting techni-
ques, which fail to distinguish the cellular source of
the mRNA, it is not clear from these experiments
which cells contain the S100A4. This is an important
point because S100A4 is present in blood vessels [15]
and in ¢broblastic cells [9], and both these cell types
are present in normal tissues and their tumours.
A preliminary immunocytochemical approach, in
which a small panel of tumours was stained using
antibodies to ¢ve S100 proteins, suggested that spe-
ci¢c antibodies to S100A4 stained the cancer cells in
breast specimens, and variable expression was de-
tected in colon and ovarian cancer specimens [66].
In contrast, experiments aimed speci¢cally at detect-
ing S100 proteins in normal skin and its lesions, in-
cluding malignant melanomas, using highly speci¢c
antibodies, found the staining for S100A4 to be weak
and thus uninformative [67]. In contrast, in colonic
lesions, immunocytochemically detected S100A4 was
not found in adenoma specimens, but was detectable
in 44% of foci of carcinoma within adenoma speci-
mens, and 94% of colon carcinoma specimens stained
immunocytochemically for S100A4. Furthermore,
and more interestingly, all the carcinoma cells in 14
metastases of the liver were immunocytochemically
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stained positive for S100A4 [16], a result that
strongly supports a role for S100A4 in the metastasis
of natural cancers.
So far, the limited data on human tumour speci-
mens suggests that there is a relationship between the
level of S100A4 and the metastasis/malignancy of
cancer cells; however, in order to establish any prog-
nostic signi¢cance, it will be necessary to use archival
specimens for which su⁄cient time has elapsed so
that intratumoral levels of S100A4 can be correlated
with the outcome of the disease. For breast cancer
this requires both a large patient base and follow-up
periods of 10 years or more.
Although it has been possible to establish a causal
link between S100A4 and metastasis of cancer cells,
it will be more di⁄cult to demonstrate the causal
mechanisms involved. Current knowledge points to
cell motility as the most likely target of overex-
pressed S100A4, and more detailed examination of
the molecules involved in this process will undoubt-
edly shed light upon the mechanism of action of
S100A4 in normal and cancer cells.
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